Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05502237, led by Gilead Sciences with Arcus Biosciences, and active but no longer recruiting when checked on 2026-09-11. Official title: A Randomised, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumour Aberrations. Planned enrolment is 1021 participants (actual). The study started in 2022-10-12 and primary completion is expected in 2028-06. No results have been posted on ClinicalTrials.gov.